Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 8, 2016, covers events occurring on June 6, 2016. Lexaria Bioscience Corp., a Nevada corporation, reported the closing of a private placement equity financing and the engagement of an investor relations firm.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: The company raised gross proceeds of US$77,000 (CDN $100,000).
- Securities Issued: 700,000 equity units were sold at US$0.11 per unit. Each unit consists of one common share and one-half of a warrant.
- Warrant Terms: Warrants allow the purchase of one additional common share at US$0.14 for three years.
- Use of Proceeds: Funds are designated for hemp-based food product deployment and marketing, investor relations, general and administrative (G&A) expenses, and working capital.
- Compensation Costs: The company agreed to pay CDN $6,000 per month (approx. US$55,400 total) to Frontier Merchant Capital Group for a 12-month contract.
Material Changes and Agreements
The filing details the entry into a material definitive agreement with Frontier Merchant Capital Group to increase market awareness through financial market communication initiatives and broker introductions in Canada, the US, and potentially Europe. Additionally, the company issued 300,000 stock options to Frontier (exercise price US$0.14, immediate vesting) and 25,000 stock options to a consultant (exercise price US$0.14, immediate vesting).
Outlook, Risks, and Contingencies
The securities issued in the private placement are subject to hold periods: four months and one day in Canada, and six months and one day for resales into the USA under Rule 144. The filing notes that the Private Placement is subject to normal regulatory approvals. The securities have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the actual cash receipt of the US$77,000 gross proceeds from the private placement.
- Confirm the regulatory approvals required for the private placement have been obtained.
- Review the specific terms of the consulting agreement with Frontier Merchant Capital Group regarding performance metrics.
- Monitor the dilution impact from the issuance of 700,000 shares, 300,000 options to Frontier, and 25,000 options to a consultant.
- Check subsequent filings for the utilization of funds against the stated purposes (hemp product marketing and G&A).